"Good morning.  Does anyone have any thoughts or comments on last week's poster presentation in Europe?"

There was an oral presentation, a poster presentation, and a Resverlogix sponsored symposium. Are you referring to the FGF23 poster? Seems like FGF23 is another great biomarker associated with CVD and CKD that Resverlogix has shown is beneficially modulated by apabetalone.

Apabetalone, a Selective Bromodomain and Extra-Terminal (BET) Inhibitor, Reduces Serum FGF23 in Cardiovascular Disease and Chronic Kidney Disease Patients.

From the poster:

"•FGF23 is an independent marker for CV risk in various patient populations, including CKD.

• Elevated FGF23 has been linked to increased risk of mortality, left-ventricular dysfunction, cardiac hypertrophy, vascular and endothelial dysfunction, and progression of CKD.

• BET inhibition by apabetalone demonstrates consistent reduction of serum FGF23 in CVD and renally impaired CKD patients.

• Patients at higher risk of adverse events and endpoints (those with above median serum FGF23 levels, and patients with CKD) demonstrate more pronounced reduction of circulating FGF23 as a result of apabetalone treatment.

• The impact of chronic treatment with apabetalone on biomarkers, renal function, and CVD outcomes." 

Sounds good to me!

BDAZ